An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
A phase 3 trial of Melphalan in melanoma and uveal melanoma, run by Delcath Systems Inc., active and no longer recruiting.
Overview
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma is a phase 3 interventional study registered as NCT05022901 by Delcath Systems Inc., with 30 participants planned, started 2022-06-10 and due to reach its primary completion in 2024-03-01. Interventions recorded: Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS). Conditions listed: Metastatic Ocular Melanoma, Metastatic Uveal Melanoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TreatmentMelphalan hepatic delivery system
Shares Delcath Systems, Uveal melanoma.
- TrialEvaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatme
Shares Delcath Systems, Melphalan (including hepatic delivery system).
- JournalMelanoma research
Shares Uveal melanoma, Melanoma.
- JournalPigment cell & melanoma research
Shares Uveal melanoma, Melanoma.
- TrialA Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Shares Uveal melanoma, Melanoma.
- TrialDual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
Shares Uveal melanoma, Melanoma.
- TrialA Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Shares Uveal melanoma, Melanoma.
- TrialA Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult P
Shares Uveal melanoma, Melanoma.